Markets
markets

West Pharmaceutical rockets on surging GLP-1 demand

West Pharmaceutical, a company that sells a tiny rubber component of GLP-1 pens, is up more than 20% after it reported earnings that crushed Wall Street estimates thanks to soaring demand for the weight-loss drugs.

The company reported adjusted earnings per share of $1.84, compared to the $1.51 analysts polled by FactSet were expecting. It also reported $766.5 million in sales, more than the $726.1 million the Street was penciling in.

Screenshot 2025-07-24 at 11.14.42 AM
Rubber elastomers used in GLP-1 pens (West Pharmaceutical Services)

The company attributed the strong report to growth in its GLP-1 elastomers, which are small rubber components that go into the pens that deliver the blockbuster weight-loss drugs made by Novo Nordisk and Eli Lilly. Those parts accounted for 8% of sales for the quarter, the company said.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.